Joe Cavaluzzi is a contributor to Real Estate New Jersey, from which this article was excerpted.
The life sciences, including pharmaceutical companies and biotech, have been a crucial part of New Jersey's economic growth both historically and during recent economic expansions. Their space requirements have created demand across all types of New Jersey commercial and industrial real estate. In fact, New Jersey is home to more pharmaceutical companies than any other state in the country, or any other country in the world, according to the HealthCare Institute of New Jersey, a Bridgewater-based industry trade association made up of 25 pharmaceutical and medical technology companies.
But the state has been feeling the pressure from other, less expensive and less tax-laden regions in eastern Pennsylvania as well as southern and other northeastern states that are experiencing growth and gaining critical mass in the life science segments of their economies. The American pharmaceutical industry has grappled with layoffs and spending cuts and recently released statistics showing that drug makers continue to struggle with the discovery of blockbuster medicines.
In addition, many of the major pharmaceutical companies with a significant New Jersey presence are trying to cope with the competition from generic drug companies. The Food and Drug Administration approved only 17 new drugs last year, matching the lowest number of newly approved compounds since the peak of 53 approvals a decade ago.
Continue Reading for Free
Register and gain access to:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.